Third, the FDA approved quizartinib in 2023, in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy for the treatment of FLT3 ITD-positive AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.